Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Prep: Cook: Serves:

Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions.

The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year.

Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising programs.”

To read more on this topic click here.

For more information on Parkinson’s treatments please visit Parkinson’s Europe website

New smart glasses could track Parkinson’s symptoms

Last Month

Next Month

Go Back

Share this story

Comments

Global update

#UniteForParkinsons around the world

The 2018 #UniteForParkinsons campaign reaches 8 million

Young-onset Parkinson’s disease: the challenges and treatment options

Mother of schoolgirl who met Sir Billy Connolly “blown away” by daughter’s selflessness

Abby has raised more than UK £1,200 for Parkinson’s

Is dry eye disease common in people with Parkinson’s?

Dry eye disease can involve symptoms such as a lower blinking rate and typically occurs when the eyes are not effectively moistened by tears – leading to discomfort and possible vision loss. Now, a recent study from Japan has investigated the previously underexplored relationship between dry eye disease and Parkinson’s. As part of their research, the team analysed 13 studies published between 2004 and 2022, which involved more than 1,500 people with Parkinson’s. Five of the reports highlighted the prevalence of dry eye disease in people with the condition – with 61% experiencing symptoms. “Our findings emphasize the need for clinicians to be vigilant of the presence of dry eye disease when managing [people with Parkinson’s],” the researchers wrote. However, they noted that more research is needed – especially “future large-scale studies” – to help understand the relationship between dry eye disease and the condition.

Highlighting dental care needs among people with Parkinson’s disease

Researchers from the University of Copenhagen, Denmark, have published a new study looking into dental care among people with Parkinson’s. Using a national register to obtain data relating to dental care between 2015 and 2019, the team identified 6,874 people with Parkinson’s, whose data was then compared to a control group of 34,285 people without the condition. A key takeaway from the five-year study was that a larger portion of people with Parkinson’s were not regular users of the dental care system – 21%, compared to 16.9% in the control group. The findings published in the journal ‘Community Dentistry and Oral Epidemiology’ also revealed that people with Parkinson’s utilised more dental-related treatment services than those in the control group – such as fillings and extractions. The researchers concluded: “This knowledge can be used by clinicians and decision-makers to ensure the optimal dental care for persons with Parkinson’s.”

Could risk factors for Parkinson’s disease be “largely man-made”?

New research has highlighted evidence of a potential link between Parkinson’s risk and exposure to toxic environmental factors – including air pollutants and human-made materials. The research was presented at the 147th Annual Meeting of the American Neurological Association in Chicago, US, as part of a symposium on neurological disorders. The evidence included a study that highlighted that exposure to toxic pollutants may activate genes associated with the condition and that current environmental policies fail to consider the potential long-term effects of neurotoxic chemicals. “The world’s fastest-growing brain disease is largely man-made,” said neurologist Dr Ray Dorsey, one of the symposium speakers, in a press release. “The principal causes are toxic exposures to chemicals synthesised in the labs of chemical companies.” Calling for greater awareness surrounding the issue, he said: “If we educate the communities we’re supposed to serve, we can have them be mobilised and change the course of…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

#UniteForParkinsons around the world

Resources & Tools

Young-onset Parkinson’s disease: the challenges and treatment options

Global update

Mother of schoolgirl who met Sir Billy Connolly “blown away” by daughter’s selflessness

Is dry eye disease common in people with Parkinson’s?

Highlighting dental care needs among people with Parkinson’s disease

Could risk factors for Parkinson’s disease be “largely man-made”?

{title}

Subscribe

Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Last Month

Next Month

Share this story

Comments

Related articles

Global update

#UniteForParkinsons around the world

Resources & Tools

Young-onset Parkinson’s disease: the challenges and treatment options

Global update

Mother of schoolgirl who met Sir Billy Connolly “blown away” by daughter’s selflessness

Is dry eye disease common in people with Parkinson’s?

Highlighting dental care needs among people with Parkinson’s disease

Could risk factors for Parkinson’s disease be “largely man-made”?

{title}

Subscribe

Sign in